A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...
A team from the Research Institute of the McGill University Health Center (The Institute), led by Jean-Jacques Lebrun, Ph.D., ...
Scientists at Oregon Health and Science University have discovered that cells generate steady internal fluid currents, dubbed ...
Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...
A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...
This phenomenon allows cancer cells to more easily spread. Courtesy of UC San Diego Health Sciences. Breast cancer frequently ...
Using a variety of laboratory and animal models, the team found that cysteine fuels the production of the antioxidant ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, ...
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into ...
In A Nutshell A common blood pressure drug, telmisartan, boosted the effectiveness of a cancer drug in lab and mouse studies.
Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...
Paras Gaur, a postdoctoral researcher at the University of Iowa, investigates DNA damage repair and G-quadruplex structures ...